~~<i id='70AE2F43AD'><strike id='70AE2F43AD'><tt id='70AE2F43AD'><pre id='70AE2F43AD'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：entertainment 2025-09-30 04:43:52 Page View：818

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Choosing scientific sides in the fight against Alzheimer's
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

focus

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

U.K. considers world's first use of meningitis vaccine to address gonorrhea

ColorizedscanningelectronmicrographofNeisseriagonorrhoeaebacteria,whichcausesgonorrhea.NIAIDAnexpert

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Surge of respiratory disease in China has likely explanation

ParentstaketheirchildrentoseeadoctoratthepediatricemergencydepartmentofahospitalinShanghai.Costfoto/